“Bimekizumab efficacy and safety through two years in patients with moderate psoriasis: Analysis of pooled data from five phase 3/3b clinical trials” (2022) SKIN The Journal of Cutaneous Medicine, 6(6), p. s67. doi:10.25251/skin.6.supp.67.